Actually, this issue is of great interest to us, first of all, because it could give us a renewed optimism. It would also give us a better understanding of the pathogenesis of long COVID‑19.
As far as the numbers are concerned, studies in the United Kingdom suggested that vaccination reduced the risk of long COVID‑19 by 50%. It was very optimistic indeed. Then another study from the United States suggested that the risk was just under 50%, so 15%.
Of course, studies have their limitations, and each is based on data that differs from study to study. That being said, what we are finding is that vaccination could be beneficial. We know that, first, people who don't get COVID‑19 are less likely to get long COVID‑19. Second, people who don't have serious illnesses that could lead them to intensive care or hospital admission on a regular basis have a better chance of avoiding the very distinct complications that affect the group of people with serious illnesses.
For the remaining 90% of those with COVID‑19 who were not hospitalized, there may be a decrease in the number of long COVID‑19 cases, but it doesn't go away. So there is certainly a need for other approaches and treatments.
Another important question to ask is what would be the effect of the treatments used in the acute phase of COVID‑19 in terms of possibly decreasing the chances of the person having long‑term complications.